Aura Biosciences, Inc. (AURA) News
Filter AURA News Items
AURA News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
AURA News Highlights
- AURA's 30 day story count now stands at 2.
- Over the past 4 days, the trend for AURA's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- DRUG and SAR are the most mentioned tickers in articles about AURA.
Latest AURA News From Around the Web
Below are the latest news stories about AURA BIOSCIENCES INC that investors may wish to consider to help them evaluate AURA as an investment opportunity.
Wall Street Analysts Think Aura Biosciences, Inc. (AURA) Could Surge 174.29%: Read This Before Placing a BetThe average of price targets set by Wall Street analysts indicates a potential upside of 174.3% in Aura Biosciences, Inc. (AURA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. |
Aura Biosciences Announces First Patient Dosed in Global Phase 3 CoMpass Trial Evaluating the Safety and Efficacy of Belzupacap Sarotalocan (Bel-sar) for First-Line Treatment of Early-Stage Choroidal MelanomaBOSTON, December 07, 2023--Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced the first patient has been dosed in the global Phase 3 CoMpass trial evaluating the safety and efficacy of bel-sar for the first-line treatment of adult patients with early-stage choroidal melanoma. |
Wall Street Analysts Believe Aura Biosciences, Inc. (AURA) Could Rally 200.75%: Here's is How to TradeThe consensus price target hints at a 200.8% upside potential for Aura Biosciences, Inc. (AURA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term. |
David Johnson Bought 232% More Shares In Aura BiosciencesThose following along with Aura Biosciences, Inc. ( NASDAQ:AURA ) will no doubt be intrigued by the recent purchase of... |
Aura Biosciences Reports Third Quarter 2023 Financial Results and Provides Clinical Development and Operational HighlightsBOSTON, November 09, 2023--Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today reported financial results for the third quarter ended September 30, 2023, and provided clinical development and operational highlights. |
Aura Biosciences to Participate in Upcoming Investor ConferencesBOSTON, November 08, 2023--Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced that Elisabet de los Pinos, PhD, Chief Executive Officer, will participate in the following upcoming investor conferences: |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on TuesdayIt's time for another dive into the biggest pre-market stock movers as we break down all of the latest news for Tuesday morning. |
Aura Biosciences Announces Pricing of Public Offering of Common StockBOSTON, November 07, 2023--Aura Biosciences, Inc. ("Aura") (Nasdaq: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced the pricing of an underwritten public offering of 11,000,000 shares of its common stock at a price to the public of $9.00 per share. The gross proceeds from the offering to Aura are expected to be $99.0 million, before deducting underwriting discounts and commissio |
Aura Biosciences Announces Proposed Public Offering of Common StockBOSTON, November 06, 2023--Aura Biosciences, Inc. ("Aura") (Nasdaq: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced the launch of an underwritten public offering of its common stock. All shares of common stock to be sold in the offering will be offered by Aura. Aura also intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its co |
Aura Biosciences Receives FDA Agreement Under Special Protocol Assessment (SPA) for CoMpass Phase 3 Clinical Trial of Belzupacap Sarotalocan (Bel-sar) in Early-stage Choroidal MelanomaBOSTON, November 06, 2023--Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced it has received agreement from the U.S. Food and Drug Administration (FDA) under an SPA for the design and planned analysis of CoMpass, the Company’s global Phase 3 clinical trial of bel-sar for the first-line treatment of adult patients with early-stage choroidal melanoma |